• Nurix Therapeutics reported past first-quarter 2026 earnings, with revenue of US$6.25 million versus US$18.45 million a year earlier and a net loss of US$87.17 million versus US$56.35 million.
• The wider basic loss per share from continuing operations, US$0.79 compared with US$0.67, highlights how the company’s cost and revenue profile has shifted year over year.
• With these results showing sharply lower revenue, we’ll now examine how this development shapes Nurix Therapeutics’ investment narrative and outlook.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is Nurix Therapeutics' Investment Narrative?

For Nurix, being a shareholder really comes down to believing that its protein degradation platform and early oncology pipeline can eventually justify years of heavy investment and continuing losses. The latest quarter’s sharp drop in revenue to US$6.25 million and wider net loss of US$87.17 million does not change the core story, but it does sharpen focus on liquidity and the timing of potential milestones from partners like Gilead and Sanofi. With the stock still up strongly over twelve months and trading on a high sales multiple, the Q1 numbers may temper enthusiasm around short term catalysts such as further clinical readouts or business development news, at least until investors gain more clarity on cash burn and funding plans. That risk is now a more immediate part of the Nurix thesis.

However, one specific funding-related risk here is something investors should not overlook. According our valuation report, there's an indication that Nurix Therapeutics' share price might be on the expensive side.

Exploring Other Perspectives

The single fair value estimate from the Simply Wall St Community sits at US$30.24, highlighting one firmly held view. You might weigh that against Nurix’s widening losses and elevated cash needs, which could shape how the story unfolds from here.

Explore another fair value estimate on Nurix Therapeutics - why the stock might be worth as much as 73% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Nurix Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Nurix Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nurix Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.